Department of Ophthalmology, Auckland, New Zealand.
Department of Ophthalmology, University of Auckland, Auckland, New Zealand.
Asia Pac J Ophthalmol (Phila). 2022 May 1;11(3):287-293. doi: 10.1097/APO.0000000000000525.
Artificial intelligence (AI) technology is poised to revolutionize modern delivery of health care services. We set to evaluate the patient perspective of AI use in diabetic retinal screening.
Survey.
Four hundred thirty-eight patients undergoing diabetic retinal screening across New Zealand participated in a survey about their opinion of AI technology in retinal screening. The survey consisted of 13 questions covering topics of awareness, trust, and receptivity toward AI systems.
The mean age was 59 years. The majority of participants identified as New Zealand European (50%), followed by Asian (31%), Pacific Islander (10%), and Maori (5%). Whilst 73% of participants were aware of AI, only 58% have heard of it being implemented in health care. Overall, 78% of respondents were comfortable with AI use in their care, with 53% saying they would trust an AI-assisted screening program as much as a health professional. Despite having a higher awareness of AI, younger participants had lower trust in AI systems. A higher proportion of Maori and Pacific participants indicated a preference toward human-led screening. The main perceived benefits of AI included faster diagnostic speeds and greater accuracy.
There is low awareness of clinical AI applications among our participants. Despite this, most are receptive toward the implementation of AI in diabetic eye screening. Overall, there was a strong preference toward continual involvement of clinicians in the screening process. There are key recommendations to enhance the receptivity of the public toward incorporation of AI into retinal screening programs.
人工智能（AI）技术有望彻底改变现代医疗服务的提供方式。我们旨在评估患者对糖尿病视网膜筛查中 AI 使用的看法。
调查。
新西兰各地 438 名接受糖尿病视网膜筛查的患者参与了一项关于他们对视网膜筛查中 AI 技术看法的调查。该调查由 13 个问题组成，涵盖了对 AI 系统的认识、信任和接受度等主题。
平均年龄为 59 岁。大多数参与者为新西兰欧洲人（50%），其次是亚洲人（31%）、太平洋岛民（10%）和毛利人（5%）。尽管 73%的参与者了解 AI，但只有 58%听说过它在医疗保健中的应用。总体而言，78%的受访者对 AI 在其护理中的使用感到满意，其中 53%表示他们会像信任医疗保健专业人员一样信任 AI 辅助筛查计划。尽管对 AI 的认识较高，但年轻参与者对 AI 系统的信任度较低。更多的毛利人和太平洋岛民参与者表示倾向于由人类主导的筛查。AI 的主要预期收益包括更快的诊断速度和更高的准确性。
我们的参与者对临床 AI 应用的认识较低。尽管如此，大多数人还是对在糖尿病眼病筛查中实施 AI 持欢迎态度。总体而言，人们强烈倾向于继续让临床医生参与筛查过程。有一些关键建议可以提高公众对将 AI 纳入视网膜筛查计划的接受程度。
